Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ZimVie Inc. - Common Stock (NQ:ZIMV)

8.925 -0.465 (-4.95%)
Streaming Delayed Price Updated: 3:58 PM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ZimVie Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Brace for Impact: 7 Stocks to Sell Amid Rising Troubles
Although few really enjoy talking about the subject, targeting stocks to sell is just as important for success as acquiring good ideas. 
Via InvestorPlace
ZimVie Announces the Launch of Azure™ Multi-Platform Product Solutions
New offerings expand ZimVie’s dental solutions for lab customers, enhancing selection and broadening the reach of the ZimVie portfolio 
From ZimVie Inc.
Via GlobeNewswire
ZimVie to Report Third Quarter 2023 Financial Results on November 1, 2023
From ZimVie Inc.
Via GlobeNewswire
ZimVie Announces the Recent Launch of Biotivity™ A/C Plus Membrane
New offering broadens ZimVie’s dental portfolio into the expanding growth factor biomaterials market 
From ZimVie Inc.
Via GlobeNewswire
Barclays Maintains Underweight Rating for ZimVie: Here's What You Need To Know
Via Benzinga
ZimVie (ZIMV) Q2 2023 Earnings Call Transcript
ZIMV earnings call for the period ending June 30, 2023. 
Via The Motley Fool
ZimVie Announces FDA Approval to Launch Mobi-C® Hybrid Study
Decision clears the way for enrollment of U.S. patients in a groundbreaking clinical study of cervical arthroplasty adjacent to fusion 
From ZimVie Inc.
Via GlobeNewswire
ZimVie Expands Development Cooperation Agreement with Brainlab AG to Include Co-Marketing
From ZimVie Inc.
Via GlobeNewswire
ZimVie Announces FDA Approval for New Mobi-C® Implant
Smaller height implants in all Mobi-C footprints to address patient anatomy 
From ZimVie Inc.
Via GlobeNewswire
ZimVie's Earnings Outlook
Via Benzinga
ZimVie's Return On Capital Employed Insights
Via Benzinga
ZimVie (ZIMV) Q1 2023 Earnings Call Transcript
ZIMV earnings call for the period ending March 31, 2023. 
Via The Motley Fool
ZimVie Reports Second Quarter 2023 Financial Results and Provides Update to Annual Guidance
From ZimVie Inc.
Via GlobeNewswire
Earnings Scheduled For August 2, 2023
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (NYSE:EDV) is estimated to report quarterly earnings at $0.37 per share on revenue of $784.53 million. 
Via Benzinga
ZimVie to Report Second Quarter 2023 Financial Results on August 2, 2023
From ZimVie Inc.
Via GlobeNewswire
ZimVie: Q1 Earnings Insights
Via Benzinga
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived... 
Via Benzinga
ZimVie to Present at the Stifel 2023 Jaws & Paws Conference
From ZimVie Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
ZimVie Reports First Quarter 2023 Financial Results and Provides Update to Annual Guidance
From ZimVie Inc.
Via GlobeNewswire
ZimVie Opens State-of-the-Art Dental Science Educational and Training Institute in Palm Beach Gardens, Florida
Modernized 11,000 sq. ft. facility equipped for hands-on dental education and training underscores company’s commitment to lead the industry in advancing professional development of dental... 
From ZimVie Inc.
Via GlobeNewswire
ZimVie Announces the Recent Launches of RegenerOss® CC Allograft Particulate and RegenerOss® Bone Graft Plug
New offerings in ZimVie’s extensive portfolio of dental bone graft solutions enhance selection for customers and bolster cadence of recent product launches 
From ZimVie Inc.
Via GlobeNewswire
ZimVie to Report First Quarter 2023 Financial Results on May 3, 2023
From ZimVie Inc.
Via GlobeNewswire
ZimVie Announces Expanded Reimbursement and Exemplary Clinical Rating for Mobi-C®
Mobi-C obtains French government reimbursement and the highest quality rating from the British clinical data panel ODEP 
From ZimVie Inc.
Via GlobeNewswire
ZimVie’s Exclusive Puros® Cancellous Particulate Allograft Dental Bone Grafting Solution Excels in Landmark Comparative Study in The International Journal of Oral & Maxillofacial Implants
Publication highlights Puros Cancellous Particulate Allograft’s collagen microstructure and greater surface area for significantly higher mesenchymal stromal cellular (hBMSC) response compared to... 
From ZimVie Inc.
Via GlobeNewswire
ZimVie Announces Additional Positive Policy Decisions for Vertebral Body Tethering
The Tether™ device now deemed “medically necessary” for the treatment of pediatric scoliosis in additional patients covered by Highmark and BCBS North Dakota 
From ZimVie Inc.
Via GlobeNewswire
(ZIMV) - Analyzing ZimVie's Short Interest
ZimVie's (NASDAQ:ZIMV) short percent of float has fallen 84.44% since its last report. The company recently reported that it has 774 thousand shares sold short, which is 3.7% of all regular shares that... 
Via Benzinga
Why ZimVie Stock Was Plummeting on Thursday
The specialty healthcare devices and tech purveyor disappointed with both fourth-quarter figures and full-year guidance. 
Via The Motley Fool
Dow Jumps Over 300 Points; Best Buy Profit Beats Views
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 300 points on Thursday. The Dow traded up 0.97% to 32,978.95 while the NASDAQ rose 0.59% to 11,446.55. The S&P... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.